Global Information
회사소개 | 문의

모세혈관확장성 운동실조증(루이스-바 증후군) : 세계 임상시험 리뷰

Ataxia-Telangiectasia (Louis-Bar Syndrome) Global Clinical Trials Review, H1, 2017

리서치사 GlobalData
발행일 2017년 04월 상품 코드 170833
페이지 정보 영문 43 Pages
가격
US $ 2,500 ₩ 2,846,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,692,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,538,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


모세혈관확장성 운동실조증(루이스-바 증후군) : 세계 임상시험 리뷰 Ataxia-Telangiectasia (Louis-Bar Syndrome) Global Clinical Trials Review, H1, 2017
발행일 : 2017년 04월 페이지 정보 : 영문 43 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

모세혈관확장성 운동실조증(루이스-바 증후군)(Ataxia-Telangiectasia (Louis-Bar Syndrome)) 치료제에 관한 임상시험의 최신 동향에 대해 분석했으며, G7(주요 7개국) 및 E7(신흥 7개국)의 임상시험 건수, 피험자수, 유망한 스폰서, 임상시험에 참여하고 있는 주요 기업과 기관, 유망한 약제 등의 정보를 전해드립니다.

본 보고서의 개요

각 지역의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 아시아태평양 지역 주요 국가의 임상시험 건수
    • 유럽 주요 5개국의 임상시험 건수
    • 북미 주요 국가의 임상시험 건수
    • 중동 및 아프리카 주요 국가의 임상시험 건수
    • 중남미 주요 국가의 임상시험 건수

G7 국가의 임상시험 건수 : 중추신경계 질환 치료제 임상시험에서 모세혈관확장성 운동실조증(루이스-바 증후군)의 비율

G7 국가의 단계별 임상시험 건수

G7 국가의 임상시험 건수 : 진행 상황별

E7 국가의 임상시험 건수 : 중추신경계 질환 치료제 임상시험에서 모세혈관확장성 운동실조증(루이스-바 증후군)의 비율

단계별 임상시험 건수

  • 진행중인 임상시험 : 단계별

진행 상황별 임상시험 건수

임상시험 목표 달성 상황

일정기간에 채용된 피험자

스폰서 종류별 임상시험 건수

유망한 스폰서

모세혈관확장성 운동실조증(루이스-바 증후군) 치료제 임상시험에 참여하고 있는 주요 기업

유망한 약제

임상시험 프로파일 개요

부록

KSM 16.10.04

영문목차

GlobalData's clinical trial report, "Ataxia-Telangiectasia (Louis-Bar Syndrome) Global Clinical Trials Review, H1, 2017" provides an overview of Ataxia-Telangiectasia (Louis-Bar Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Ataxia-Telangiectasia (Louis-Bar Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28

Appendix 40

  • Abbreviations 40
  • Definitions 40
  • Research Methodology 41
  • Secondary Research 41
  • About GlobalData 42
  • Contact Us 42
  • Source 43

List of Tables

List of Tables

  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 9
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
  • Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 14
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Ataxia-Telangiectasia (Louis-Bar Syndrome) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 17
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27

List of Figures

List of Figures

  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Ataxia-Telangiectasia (Louis-Bar Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Ataxi
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research